TY - JOUR
T1 - A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation
AU - Regeneron Genetics Center
AU - Geisinger-Regeneron DiscovEHR Collaboration
AU - EPoS Consortium
AU - VA Million Veteran Program
AU - Vujkovic, Marijana
AU - Ramdas, Shweta
AU - Lorenz, Kim M.
AU - Guo, Xiuqing
AU - Darlay, Rebecca
AU - Cordell, Heather J.
AU - He, Jing
AU - Gindin, Yevgeniy
AU - Chung, Chuhan
AU - Myers, Robert P.
AU - Schneider, Carolin V.
AU - Park, Joseph
AU - Lee, Kyung Min
AU - Serper, Marina
AU - Carr, Rotonya M.
AU - Kaplan, David E.
AU - Haas, Mary E.
AU - MacLean, Matthew T.
AU - Witschey, Walter R.
AU - Zhu, Xiang
AU - Tcheandjieu, Catherine
AU - Kember, Rachel L.
AU - Kranzler, Henry R.
AU - Verma, Anurag
AU - Giri, Ayush
AU - Klarin, Derek M.
AU - Sun, Yan V.
AU - Huang, Jie
AU - Huffman, Jennifer E.
AU - Townsend Creasy, Kate
AU - Hand, Nicholas J.
AU - Liu, Ching Ti
AU - Long, Michelle T.
AU - Yao, Jie
AU - Budoff, Matthew
AU - Tan, Jingyi
AU - Li, Xiaohui
AU - Lin, Henry J.
AU - Chen, Yii Der Ida
AU - Taylor, Kent D.
AU - Chang, Ruey Kang
AU - Krauss, Ronald M.
AU - Vilarinho, Silvia
AU - Brancale, Joseph
AU - Nielsen, Jonas B.
AU - Locke, Adam E.
AU - Jones, Marcus B.
AU - Verweij, Niek
AU - Baras, Aris
AU - Pyarajan, Saiju
N1 - Funding Information:
This research is based on data from the MVP, Office of Research and Development, Veterans Health Administration and was supported by award MVP000. This publication does not represent the views of the Department of Veterans Affairs, the US Food and Drug Administration or the US Government. This research was also supported by funding from the Department of Veterans Affairs awards I01- BX003362 (P.S.T. and K.-M.C.) and I01 BX003341 (H.R.K. co-principal investigator) and the VA Informatics and Computing Infrastructure VA HSR RES 130457 (S.L.D. and J.A.L.). B.F.V. acknowledges support for this work from the National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (grants DK101478 and DK126194) and a Linda Pechenik Montague Investigator award. K.-M.C., S.M.D., J.M.G., C.J.O., L.S.P. and P.S.T. are supported by the VA Cooperative Studies Program. S.M.D. is supported by the VA (IK2 CX001780). Funding support is also acknowledged for M.S. (K23 DK115897), R.M.C. (R01 AA026302), D.E.K. (T32 HL007734), A.D.W. (R01 DK122586, R01 AI123539), J.B.M. (R01 HL151855, UM1 DK078616), W.R.W. (R01 HL137984 P41 EB029460), S.F.A.G. (R01 HD056465), L.B. (R01 LM010685), A.V.K. (K08 HG010155, U01 HG011719) and L.S.P. (VA awards CSP #2008, I01 CX001899, I01 CX001737 and I01 BX005831; NIH awards R01 DK127083, R03 AI133172, R21 AI156161, UL1 TR002378 and P30 DK111024; and Cystic Fibrosis Foundation award PHILLI12A0). The Rader lab was supported by NIH grants HL134853 (N.J.H. and D.J.R.) and DK114291-01A1 (K.T.C., N.J.H. and D.J.R.). We thank all study participants for their contribution. Support for imaging studies was provided by the University of Pennsylvania’s Institute for Translational Medicine and Therapeutics (NIH NCATS UL1 TR001878), the Penn Center for Precision Medicine Accelerator Fund.
Publisher Copyright:
© 2022, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
PY - 2022/6
Y1 - 2022/6
N2 - Nonalcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease. Using a proxy NAFLD definition of chronic elevation of alanine aminotransferase (cALT) levels without other liver diseases, we performed a multiancestry genome-wide association study (GWAS) in the Million Veteran Program (MVP) including 90,408 cALT cases and 128,187 controls. Seventy-seven loci exceeded genome-wide significance, including 25 without prior NAFLD or alanine aminotransferase associations, with one additional locus identified in European American-only and two in African American-only analyses (P < 5 × 10−8). External replication in histology-defined NAFLD cohorts (7,397 cases and 56,785 controls) or radiologic imaging cohorts (n = 44,289) replicated 17 single-nucleotide polymorphisms (SNPs) (P < 6.5 × 10−4), of which 9 were new (TRIB1, PPARG, MTTP, SERPINA1, FTO, IL1RN, COBLL1, APOH and IFI30). Pleiotropy analysis showed that 61 of 77 multiancestry and all 17 replicated SNPs were jointly associated with metabolic and/or inflammatory traits, revealing a complex model of genetic architecture. Our approach integrating cALT, histology and imaging reveals new insights into genetic liability to NAFLD.
AB - Nonalcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease. Using a proxy NAFLD definition of chronic elevation of alanine aminotransferase (cALT) levels without other liver diseases, we performed a multiancestry genome-wide association study (GWAS) in the Million Veteran Program (MVP) including 90,408 cALT cases and 128,187 controls. Seventy-seven loci exceeded genome-wide significance, including 25 without prior NAFLD or alanine aminotransferase associations, with one additional locus identified in European American-only and two in African American-only analyses (P < 5 × 10−8). External replication in histology-defined NAFLD cohorts (7,397 cases and 56,785 controls) or radiologic imaging cohorts (n = 44,289) replicated 17 single-nucleotide polymorphisms (SNPs) (P < 6.5 × 10−4), of which 9 were new (TRIB1, PPARG, MTTP, SERPINA1, FTO, IL1RN, COBLL1, APOH and IFI30). Pleiotropy analysis showed that 61 of 77 multiancestry and all 17 replicated SNPs were jointly associated with metabolic and/or inflammatory traits, revealing a complex model of genetic architecture. Our approach integrating cALT, histology and imaging reveals new insights into genetic liability to NAFLD.
UR - http://www.scopus.com/inward/record.url?scp=85132074767&partnerID=8YFLogxK
U2 - 10.1038/s41588-022-01078-z
DO - 10.1038/s41588-022-01078-z
M3 - Article
C2 - 35654975
AN - SCOPUS:85132074767
SN - 1061-4036
VL - 54
SP - 761
EP - 771
JO - Nature Genetics
JF - Nature Genetics
IS - 6
ER -